BSE Live
Dec 05, 16:01Prev. Close
3801.65
Open Price
3813.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 05, 15:56Prev. Close
3795.70
Open Price
3805.10
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
3785.90 (356)
| Cash Flow of Torrent Pharmaceuticals (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 2,610.18 | 1,916.57 | 1,577.02 | 1,466.21 | 1,366.11 | |
| Net CashFlow From Operating Activities | 2,574.50 | 2,893.10 | 2,265.41 | 2,140.10 | 1,578.23 | |
| Net Cash Used In Investing Activities | -470.09 | -296.07 | -2,384.07 | -159.70 | -316.28 | |
| Net Cash Used From Financing Activities | -2,104.46 | -2,577.57 | 80.74 | -1,977.27 | -1,586.54 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 58.32 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -0.05 | 19.46 | 20.40 | 3.13 | -324.59 | |
| Cash And Cash Equivalents Begin of Year | 104.86 | 85.40 | 65.00 | 61.87 | 386.46 | |
| Cash And Cash Equivalents End Of Year | 104.81 | 104.86 | 85.40 | 65.00 | 61.87 |
14.11.2025
Torrent Pharma Consolidated September 2025 Net Sales at Rs 3,302.00 crore, up 14.3% Y-o-Y
12.11.2025
Torrent Pharma Standalone September 2025 Net Sales at Rs 2,762.00 crore, up 13.48% Y-o-Y
29.07.2025
Torrent Pharma Consolidated June 2025 Net Sales at Rs 3,178.00 crore, up 11.16% Y-o-Y
29.07.2025
Torrent Pharma Standalone June 2025 Net Sales at Rs 2,616.00 crore, up 7.3% Y-o-Y
12.07.2023
Torrent Pharma Q1 PAT may dip 9.7% YoY to Rs 319.7 cr: Nirmal Bang
17.01.2023
Torrent Pharma Q3 PAT seen up 28.9% YoY to Rs 3,211 cr: Nirmal Bang
13.07.2022
Torrent Pharma Q1 PAT seen up 2.8% YoY to Rs 339.1 cr: ICICI Direct
08.07.2022
Torrent Pharmaceuticals Q1 PAT seen up 1.4% YoY to Rs 334.5 cr: Prabhudas Lilladher
24.07.2019
Torrent Pharma shares jump 6% as brokerages remain bullish after Q1 show
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
22.01.2014
14.01.2012